U.S. Markets closed

Morgan Stanley Cozies Up to Medical Marijuana Stock GWPH

Morgan Stanley has given GW Pharmaceuticals (GWPH) its vote of confidence, stamping the leader in cannabis-based drugs with a bullish "overweight" rating and a $103.00 price target for the stock on account of the upside potential of epilepsy drug Epidiolex and the company's "novel platform." Upon the pre-market release of the bank's upgrade, the stock jumped from its Monday close of $46.04 to an opening price of $50.10. And the stock continued to roar throughout the trading day Tuesday.